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coronary interventionAbstract Aim: To compare single cycle remote ischemic preconditioning (single RIPC) to multi-
ple cycles RIPC in attenuating cardiac myonecrosis and reducing MACE after elective PCI.
Methods and results: 150 consecutive patients undergoing elective PCI were studied. Mean age was
54.5 ± 7.2 years and 42(28%) patients were females. 100 patients received RIPC (each cycle of
RIPC was 5 min of inﬂation followed by 5 min of deﬂation), 50 by multiple cycles RIPC (group
A), and 50 with single cycle RIPC (group B), while 50 patients did not receive RIPC (group C, con-
trol) before PCI. Myocardial ischemia during PCI, indicated by ST-segment deviation, was less in
RIPC patients (31(31%) vs. 25(50%) patients, p= 0.023, 0.48 ± 0.81 mm vs. 0.96 ± 1.2 mm,
p= 0.004; respectively), a difference that was similar when subgroups were compared to control
(group A: 15, group B: 16, group C: 25 patients, p= 0.075, and group A: 0.46 ± 0.76, group B:
0.5 ± 0.86, group C:0.96 ± 1.2 mm, p= 0.015), with no difference between groups A and B.
Myonecrosis, indicated by mean cTnI at 24 h after PCI, was lower in RIPC (0.043 ± 0.033,
0.06 ± 0.048 ng/ml, p= 0.01), higher in the control than subgroups (group A: 0.043 ± 0.034,
group B: 0.042 ± 0.33, and group C: 0.06 ± 0.048 ng/ml, p= 0.002), again with no difference
between groups A and B. At 3 months, there was a trend toward lower MACE, which was
signiﬁcant for acute coronary syndrome, in all the RIPC groups.
Conclusion: Single-cycle RIPC can be an alternative to multiple-RIPC for protective effects after
elective PCI, however single RIPC requires less time in the busy PCI setting.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
Ischemic preconditioning (IPC), was shown to reduce the
extent of myocardial infarction (MI), and to attenuate
ischemia/reperfusion injury (IR).1–4 Later, it was found
that myocardial infarction (MI) size can be reduced if IPC
308 A.M.S. Omar, M.A. Abdel-Rahmanwas applied to a distant organ before myocardial ischemia, an
extension that was called remote IPC (RIPC).5–8
Troponin release is an accurate marker of myocyte necrosis,
used in many studies to prove the beneﬁt of IPC in decreasing
infarct size. However, elective percutaneous coronary interven-
tion (PCI) is also associated with troponin release in approxi-
mately one third of the cases,9,10 which is associated with
subsequent cardiovascular events.11
A recent study showed that RIPC reduces PCI-related cTnI
release and appears to reduce subsequent cardiovascular
events.12 In that study, RIPC was done by repeated cycles of
ischemia in the upper limb done by a blood pressure cuff inﬂa-
tion for 5 min, interrupted by 5 min of cuff deﬂation.
In this study we aim to test the hypothesis that RIPC by
single cycle of blood pressure cuff inﬂation is similar to that
by multiple cycles of blood pressure cuff inﬂations in reducing
cTnI after elective PCI compared to controls.
2. Methods
2.1. Identiﬁcation and recruitment of patients
We included patients with signiﬁcant coronary artery stenosis
suitable for PCI (i.e. not three vessel disease or other complex
lesion anatomy which are not suitable for PCI), documented
by previous coronary angiography, referred for elective PCI
in Ain Shams University Hospital and National Heart
Institute (NHI), Cairo, Egypt. Patients were excluded if their
level of cardiac troponin I (cTnI) before PCI was elevatedTable 1 Basic demographic, clinical and angiographic data for all
All patients (n= 150) Group A
Age (years) 54.5 ± 7.2 54.1 ± 7.4
Sex (m/f) n(%) 108(72)/42(28) 35(70)/15(
Risk factors n(%)
DM 79(53) 28(56)
HTN 88(59) 25(50)
DLP 9(6) 4(8)
SM 81(54) 25(50)
Family history 34(23) 11(22)
Mean blood pressure (mmHg) 97.6 ± 9.9 97.2 ± 10
Heart rate (beat/minute) 85.9 ± 5.8 86.6 ± 6.8
Medications n(%)
B-blockers 133(89) 42(84)
ACEI 100(67) 34(68)
Statins 85(57) 30(60)
Killip class (I/II) n(%) 128(85)/22(15) 43(86)/7(1
Presentation cTnI (ng/ml)a 0.024 ± 0.005 0.024 ± 0
Number of diseased vessels
Single vessel 115(77) 39(78)
Two vessels 35(23) 11(22)
Diseased vessels
LAD 94(63) 33(66)
LCX 27(18) 5(10)
RCA 44(29) 15(30)
Others 23(15) 10(20)
Number of signiﬁcant lesions 193 65
AHA class (A/B/C) 146/44/3 50/15/0
Number of lesions per patient 1.29 ± 0.45 1.3 ± 0.46
% of stenosis 84.4 ± 7.7 82.2 ± 14
a Presentation cTnI was available as a continuous variable in 98 cases (3
remaining cases were so low to be detected by the measuring device.(corresponding >0.04 ng/ml in the measurement assay used),
or if they were on nicorandil or glibenclamide use (precondi-
tioning-mimetic and preconditioning-blocking medication,
respectively).12–14
The local ethics committee of both institutions approved
the study and randomization protocol, and all patients gave
written informed consents.
2.2. Procedural interventions
2.2.1. Remote IPC and control interventions
All RIPC studies were done in the cardiac catheterization lab-
oratory, on table, and before starting the PCI procedure.
Patients randomized to have RIPC had a blood pressure cuff
placed around their non-dominant upper arm. In group A,
the cuff was inﬂated in three cycles each to 200-mmHg pres-
sure for 5 min, followed by 5 min of deﬂation, to allow reper-
fusion. In group B patients had only one cycle of inﬂation and
deﬂation. In the control group (group C), patients had a sim-
ilar cuff placed around the upper arm, but it was not inﬂated.
Thereafter, all patients underwent PCI by an interventionist
blinded to the study allocation.
2.2.2. Percutaneous coronary intervention
PCI was started once the cuff was removed after the last cycle
of inﬂation in group A, and after removal of the cuff in groups
B and C with a time window between removal of the cuff and
the ﬁrst balloon inﬂation that did not exceed 15 min. PCI was
performed via a femoral arterial approach with 6F or 7Fpatients and subgroups.
(n= 50) Group B (n= 50) Group C (n= 50) p-Value
54.0 ± 5.9 55.3 ± 8.3 .645
30) 38(76)/12(24) 35(70)/15(30) 0.743
25(50) 26(52) 0.829
29(58) 34(68) 0.187
0(0) 5(10) 0.084
31(62) 25(50) 0.381
13(26) 10(20) 0.766
.5 95.8 ± 9.6 99.7 ± 9.5 0.133
85 ± 5.7 86 ± 4.7 0.375
47(94) 44(88) 0.284
30(60) 36(72) 0.432
28(56) 27(54) 0.827
4) 40(80)/10(20) 45(90)/5(10) 0.363
.005 0.025 ± 0.005 0.022 ± 0.005 0.246
0.862
39(78) 37(74)
11(22) 13(26)
30(60) 31(62) 0.819
12(24) 10(20) 0.172
12(24) 17(34) 0.543
7(14) 6(12) 0.513
63 65
51/12/0 45/17/3 0.125
1.26 ± 0.44 1.30.46 0.880
.3 85.9 ± 7.6 85.1 ± 7.7 0.111
5 in group A, 38 in group B, and 25 in group C) because values in the
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Single vs. multiple RIPC in elective PCI 309guiding catheters. All patients received aspirin 300 mg and clop-
idogrel 300 mg at least 6 h before PCI and were anti-coagulated
with a heparin bolus (70–100 U/kg) after arterial sheath inser-
tion. All patients received aspirin 75 mg indeﬁnitely and clopido-
grel 75 mg for 4 weeks after bare metal stent implantation.
ECG changes during stent implantation were assessed.
Procedural success was deﬁned angiographically as a residual
stenosis of <15%.
Number of diseased vessels, lesional site and type, length
and type of implanted stent, duration, and pressure of coro-
nary balloon inﬂations were recorded by two interventional
cardiologists who were blinded to the cTnI results.15
2.3. Outcome measurements
2.3.1. Biochemistry
Venous blood samples were taken at baseline and 24 h after PCI
formeasuring cTnI by an automated immunoassaymethod. The
99th percentile of the cTnI level in a reference population (upper
reference limit) of healthy volunteerswas below the lower limit of
detection of 0.04 ng/mL. The analytical range was 0.02–50 ng/
mL (2), and accordingly patients who had cTnI levels
<0.02 ng/ml were expressed by the assay as non-detectable.
2.4. Three month followup
2.4.1. Major adverse cardiac events (MACE) rate
Patients were contacted by telephone 3 months after PCI and
major adverse cardiac events (MACE), including cardiac
death, hospital admissions with acute coronary syndrome
(unstable angina or myocardial infarction), and heart failure,
were recorded.
2.5. Study endpoints
The primary endpoint of this study was to test the differences
in PCI-related ST-changes (as an indicator of intraprocedural
myocardial ischemia) and cTnI concentration at 24 h between
groups. Secondary endpoint was to test the difference of
MACE at 3 month follow-up between groups.
2.6. Statistical methods and analysis
Nominal data were expressed as number (%) and were com-
pared using chi2 test. Continuous data were expressed as
mean ± SD and were compared using one-way ANOVA
and student t-test. Binominal multivariate regression model
was initiated to compare the independent prediction of
MACE at 3 months between variables that were different
between groups. P-value 6 0.05 was considered statistically
signiﬁcant. All the analyses were performed with commer-
cially available software (SPSS version 16.0, SPSS, Inc., Chi-
cago, IL, USA). The authors had full access to the data and
take full responsibility for their integrity.
3. Results
In the period between December 2010 and October 2011, 150
consecutive patients, referred to the catheterization laboratory
of Ain Shams University Hospital, Cairo, Egypt, and the
310 A.M.S. Omar, M.A. Abdel-RahmanNational Heart Institute, Cairo, Egypt, for elective PCI, who
had normal presentation cardiac troponin I (cTnI < 0.04
ng/ml) and who were suitable for stent implantation, were
included. Patients were divided into 3 groups according to the
type of RIPC used: group A: i50 patients who received 3 cuff
inﬂations as a source of RIPC, group B: included 50 patients
who received a single cuff inﬂation as a source of RIPC, and
group C: included 50 patients who did not receive any cuff
inﬂation (control group).
3.1. Basic, demographic, clinical, and angiographic data
Table 1 summarizes basic demographic, clinical and medica-
tion, in addition to basic angiographic data of all patients as
well as study groups. The mean age was 54.5 ± 7.3 years,
and 42 (28%) patients were females. All patients had normal
sinus rhythm, and all patients had no resting ST-T changes
on 12 leads electrocardiogram.
One hundred and ﬁfteen (77%) patients had one vessel dis-
ease, 35 (23%) patients had two vessel disease. The culprit ves-
sel was the left anterior descending (LAD) in 94 (63%)
patients, left circumﬂex (LCX) in 27 (18%) patients, and the
right coronary artery (RCA) in 44 (29%) patients, and other
branches in 23 (15%) patients. The number of signiﬁcant
lesions detected was 193 lesions (1.29 ± 0.45 lesion per patient,
% stenosis was 84.4 ± 7.7%).
There were no signiﬁcant differences between groups
regarding basic demographic, clinical or coronary catheteriza-
tion data.
All patients were tested for the level of cTnI before proceed-
ing to the catheterization laboratory to make sure that all
patients enrolled had pre-PCI normal cTnI levels (60.04
ng/ml). In our study, 52 patients had undetectable
(<0.02 ng/ml) pre-PCI cTnI levels, while cTnI was recorded
for 98 patients (0.024 ± 0.005 ng/ml, Table 1).
3.2. PCI procedure and outcomes
One hundred and eighty-four bare metal stents were deployed
in the 193 lesions. 116 patients had only one stent implanted
and 34 patients had two stents implanted. Mean stent length
and size were 19.9 ± 21.2 mm and 3.13 ± 0.38 mm, respec-
tively, and mean stent balloon inﬂation pressure was
11.3 ± 2.0 mmHg, and mean inﬂation time was 10.1 ± 1.3 s.
There were no major procedure-related complications in all
groups. All patients ended with TIMI-III ﬂow and no residual
stenosis or dissection after stent deployment. No signiﬁcant
differences were detected between groups regarding number
of stents implanted per patient, stent size, length, inﬂation
pressure, or inﬂation time.
3.2.1. Intraprocedural myocardial ischemia
Fifty-six patients showed ST-segment deviation on ECG dur-
ing PCI (0.64 ± 0.96 mm). There was a strong trend toward
more ST-deviation during PCI in the control group (group
A: 15 patients, group B: 16 patients, group C: 25 patients;
p= 0.075, Table 2). However, the magnitude of ST-deviation
was signiﬁcantly higher in the control group (group A:
0.46 ± 0.76 mm, group B: 0.5 ± 0.86 mm, and group C:
0.96 ± 1.2 mm, p= 0.015, Table 2, Fig. 1A). When the
comparison was done between the number of patients showingST-deviation in all patients with IPC (groups A and B) vs. con-
trols (group C), it was found that signiﬁcantly fewer patients
showed ST-segment deviation in patients who received
RIPC (RIPC: 31 patients (31%), controls: 25 patients (50%),
p= 0.023, Table 2), while the magnitude of ST-deviation
became more signiﬁcantly different (IPC: 0.48 ± 0.81 mm,
controls: 0.96 ± 1.2 mm, p= 0.004, Table 2).
3.3. Effect of IPC on cTnI levels at 24 h
Overall, the mean cTnI 24 h after PCI was 0.049 ± 0.04 ng/ml.
Abnormal cTnI levels (>0.04 ng/ml) were detected in 62(41%)
patients after PCI, which was signiﬁcantly more in group C
(group A: 17(34%) patients, group B: 17(34%) patients, group
C: 28(56%) patients, p= 0.036). There was a strong trend
toward lower levels of cTnI in group A compared to group
C (0.043 ± 0.034 vs. 0.06 ± 0.04 ng/ml patients, p= 0.073),
as well as group B compared to group C (0.042 ± 0.033 vs.
0.06 ± 0.04 ng/ml patients, p= 0.061), however, there was
no difference at all between groups A and B regarding cTnI
(p= 0.938), (Table 2 and Fig. 1B).
Moreover, out of the 62 patients with abnormal cTnI val-
ues, 16 patients (11%) had a threefold or more increase of
the cTnI values compared to baseline, a ﬁnding that was not
different between groups (group A: 4 (8%), group B: 4(8%),
group C: 8(16%), p= 0.362). However, the level of cTnI
was overall signiﬁcantly different between groups in this subset
of patients (group A: 0.142 ± 0.005 ng/ml, group B:
0.145 ± 0.01 ng/ml, group C: 0.16 ± 0.01 ng/ml, p= 0.036,
Table 2, Fig. 1B), because of a trend toward higher values if
mean cTnI in group C compared to groups A and B
(p= 0.073, 0.061).
To conﬁrm such differences, the difference between basal
and 24 h cTnI was calculated (delta-cTnI) and was
0.035 ± 0.038 ng/ml. Delta-cTnI was lower in group A com-
pared to group C (0.031 ± 0.03 vs. 0.049 ± 0.047 ng/ml,
p= 0.037), and in group B compared to group C
(0.024 ± 0.03 vs. 0.049 ± 0.047 ng/ml, p= 0.002), however,
there were no signiﬁcant differences between groups A and B
(p= 0.589) (Table 2 and Fig. 1C).
It is worth noting that similar differences were found when
we compared patients with any IPC vs. control group
(Table 2).
3.3.1. Major cardiovascular events at 3 month follow-up
Three months after PCI, 20 patients suffered P1 MACE (1
case died, 19 cases had acute coronary syndrome (ACS), and
2 cases developed heart failure). The occurrence of ACS was
signiﬁcantly more in the control group (group A: 5 cases,
group B: 3 cases, and group C: 11 cases, p= 0.044, Table 3).
Moreover, there was a trend toward higher composite of
MACE at 3 months in the control group (group A: 5 cases,
group B: 4 cases, and group C: 11 cases, p= 0.084, Table 3).
Both ACS and the composite of all MACE were signiﬁ-
cantly higher in the control group compared to all patients
with RIPC (Table 3).
Moreover, we found that the occurrence of complications
3 months after PCI was signiﬁcantly more in patients with
abnormal cTnI (15(24%) vs. 5(5.6%), p= 0.001), and was
even more signiﬁcantly higher in patients with cTnIP 3 times
the basal level (10(7.5%) vs. 10(62.5%), p< 0.001).
Figure 1 Comparisons between different groups using one way ANOVA, (A) differences in the magnitude of ST-deviation during PCI
(mm), (B) differences in cTnI levels 24 h after PCI (ng/ml), and (C) differences in delta-cTnI (ng/ml).
Single vs. multiple RIPC in elective PCI 311Multivariate binary logistic regression model found that the
presence of abnormal cTnI levels (>0.4 ng/ml) independently
predicts the occurrence of MACE at 3 months (B= 1.667,
p= 0.002, relative odds ratio = 5.3), while the presence of
ST-deviation failed to do so (B= 0.456, p= 0.482, relative
odds ratio = 1.58, Table 4).
Similarly, the occurrence of ACS 3 months after PCI was
signiﬁcantly more in patients with abnormal cTnI (15(24%)
vs. 4(4.5%), p< 0.001), and in patients with cTnIP 3 times
the basal level (10(62.5%) vs. 9(6.7%), p= 0.001).
Another multivariate binary logistic regression was initi-
ated to compare the ability of the presence of only abnormal
cTnI values at 24 h after PCI and the presence of threefold
or more increase of cTnI compared to baseline, in addition
to the presence of ST-deviation during PCI, to predict the
occurrence of MACE at 3 months post-PCI, it was found that
threefold increase in cTnI had the strongest independent pre-
dictive ability of MACE occurrence (B= 3.029, relative oddsTable 3 Complications at 3 month followup.
All patients vs. subgroups
All (n= 150) Group A (n= 50) Group B (n= 50) Group
Death 1 0(0) 1(2) 0(0)
ACS 19 5(10) 3(6) 11(22)
HF 2 0(0) 1(2) 1(2)
Composite 20 5(10) 4(8) 11(22)ratio = 20.6, p< 0.001), while the presence of only abnormal
cTnI or presence of ST-deviation failed to do so.
4. Discussion
In the present study, we have shown that single cuff inﬂation is
not inferior to multiple cuff inﬂation as a source of remote
ischemic preconditioning to attenuate cardiac myonecrosis
after elective percutaneous coronary intervention (PCI) and
to reduce major adverse cardiac event rate (MACE Rate) at
3 month followup.
4.1. Myonecrosis after PCI
Several studies have shown that PCI-related cTnI release is
associated with a worse prognosis.10,16–18 A post-procedure
increase in cTnI concentration of >5-fold was found as anAll patients who had RIPC vs. control
C (n= 50) p-Value All patients
with IPC (n= 100)
Control (n= 50) p-Value
0.365 1(1) 0(0) 0.478
0.044 8(8) 11(22) 0.015
0.602 1(1) 1(2) 0.615
0.084 9(9) 11(22) 0.027
Table 4 Multivariate binominal regression model for the prediction of MACE at 3 months.
Between ST-deviation and abnormal cTnI
values only (Cox & Snell r2 = 0.069) (Negelkerke r2 = 0.128)
All variables
(Cox & Snell r2 = 0.156) (Negelkerke r2 = 0.287)
B S.E. p-Value Relative OR B S.E. p-Value Relative OR
ST-deviation 0.456 0.648 0.482 1.577 0.23 0.796 0.773 0.795
Abnormal cTnI 1.67 0.548 0.002 5.298 0.71 0.661 0.286 2.024
cTnIP 3 times basal – – – – 3.03 0.612 <0.001 20.67
312 A.M.S. Omar, M.A. Abdel-Rahmanindependent predictor of MACE at 1 year.18 In our study, the
best predictor of MACE at 3 months after PCI was the pres-
ence of abnormal cTnI at 24 h, which was consistent with
the previous ﬁndings. cTnI at 24 h was signiﬁcantly higher
in patients who had MACE at 3 months after PCI, and,
moreover, threefold or more increase of cTnI at 24 h was more
signiﬁcant and of more predictive value.
4.1.1. Mechanism of myonecrosis after PCI
Microembolization and side-branch occlusion have been pro-
posed as mechanisms of cTnI release after PCI.19–21 A Doppler
ﬂow-wire study reported that the number of microemboli dur-
ing PCI correlated with cTnI release.22,23
A recent redeﬁnition of MI identiﬁes PCI as a cause of
MI when the postprocedure cTnI concentration rises to 3
folds compared to the baeline.24 In our study, we found that
cTnI increases P3 times the basal levels, and delta-cTnI was
signiﬁcantly higher in patients with ACS at 3 months after
PCI.
Stent length, acute gain in vessel diameter, case complexity,
and PCI-complications, have been shown to be related to PCI-
associated cTnI release.16,19–21 In our study, stent length and
size were similar between study groups, relatively simple coro-
nary anatomy was included, and no PCI-related complications
were noticed. As such, the previously mentioned factors might
not have affected our ﬁndings.
4.2. Myocardial protection by RIPC in previous studies
RIPC reportedly reduces MI size and RI, and studies have
shown that it attenuates troponin release, after coronary artery
surgery and noncardiac surgery,25–28 and during surgical cor-
rection of congenital heart defects.29
The protective role of RIPC is clearly attractive, particu-
larly for elective intervention. Porto and colleagues reported
that no myocardial protection was conferred by RIPC
induced by three cycles of bilateral upper-limb ischemia
immediately before PCI.7 In contrast, they observed that
RIPC exacerbated cTnI release after PCI and enhanced the
inﬂammatory response in low-risk patients undergoing sin-
gle-vessel elective PCI. A larger prospective randomized con-
trolled study by Hoole et al., however, found that RIPC one
hour before PCI increased the number of patients with no
detectable cTnI release at 24 h, appeared to increase myocar-
dial tolerance to ischemia,12 and improved ST-segment devi-
ation during ﬁrst coronary balloon occlusion. Our study
conﬁrms such observation, and adds that a single cycle RIPC
is of similar value.
Loukogeorgakis et al., reported that RIPC with 3 cycles
induced protection against ischemia RI, but shortening thestimulus to 2 cycles was not protective.30 They added that
tissue volume exposed to the preconditioning stimulus deter-
mined the degree of protection because 2-cycle RIPC was
effective against endothelial IR injury when applied to the
leg but not when applied to the arm. Thus, it seemed that
the preconditioning stimulus should cross a certain thresh-
old to be protective. However, the effects of 2 cycles and
3 cycles of preconditioning were compared in the brachial
artery, while in our study comparisons were done in the cor-
onary artery. Accordingly, it seems that preconditioning
threshold is different between the coronary artery and
peripheral arteries. We did not, however, study the effect
of the size of the area on which the ischemic preconditioning
stimulus is applied, as we have not studied if such a stimulus
would be different if applied on the leg compared to the
arm.
4.3. Clinical implications
Single cycle IPC gives a simple application of RIPC in a busy
PCI center, because it requires less time than multiple cycle
IPC which requires 30 min.
4.4. Study limitations
Unfortunately, the study suffers of some major limitations.
First, the small sample size, might affect the results of our
study, especially those at 3 month followup. Second, cTnI
concentration was measured in a single blood sample rather
than serial measurements, thus the included values may not
be peak plasma concentrations. Third, it is possible that if
the time lag between cuff inﬂation and intracoronary balloon
inﬂation had been shorter, the protective effect observed
would have been magniﬁed. So, further studies should
consider this issue. Finally, the followup period was short,
and another study with longer period of follow-up should
be carried out.
5. Conclusions
Remote single cycle of IPC has protective effects on the myo-
cardium same as multiple cycles of remote IPC as it similarly
increases the tolerance of the myocardium to ischemia, reduces
the prevalence of myonecrosis after elective PCI, and appears
to reduce subsequent cardiovascular events.
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